Trials / Completed
CompletedNCT03631407
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vicriviroc | Vicriviroc tablets administered orally, QD at dose level 1 or 2. |
| BIOLOGICAL | Pembrolizumab | Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1. |
Timeline
- Start date
- 2018-09-24
- Primary completion
- 2021-06-08
- Completion
- 2021-06-08
- First posted
- 2018-08-15
- Last updated
- 2024-11-21
- Results posted
- 2022-06-07
Locations
8 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03631407. Inclusion in this directory is not an endorsement.